📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
GSK Pharma to Appoint Ronojit Biswas as Whole-time Director & CFO for 3-Year Term
GlaxoSmithKline Pharmaceuticals Limited has initiated a postal ballot to seek shareholder approval for the appointment of Mr. Ronojit Biswas as a Whole-time Director and Chief Financial Officer. The proposed tenure is for three years, effective from April 1, 2026, to March 31, 2029. Shareholders can participate in the electronic voting process from March 9 to April 8, 2026, with final results expected by April 10, 2026. This leadership change is part of the company's planned management transition.
Key Highlights
Appointment of Mr. Ronojit Biswas as Whole-time Director and CFO for a 3-year term starting April 1, 2026.
E-voting period for shareholders is scheduled from March 9, 2026, to April 8, 2026.
The cut-off date for determining shareholder eligibility for voting was February 27, 2026.
The results of the postal ballot will be officially announced on or before April 10, 2026.
💼 Action for Investors
Investors should take note of the leadership transition and monitor the official announcement of voting results on April 10, 2026. No immediate portfolio action is required as this is a standard management appointment.
GSK Pharma to Appoint Ronojit Biswas as WTD & CFO for 3-Year Term
GlaxoSmithKline Pharmaceuticals Limited has issued a postal ballot notice seeking shareholder approval for the appointment of Mr. Ronojit Biswas as a Whole-time Director and Chief Financial Officer. The proposed appointment is for a period of three years, effective from April 1, 2026, to March 31, 2029. Shareholders can participate in the decision via remote e-voting, which is scheduled to take place between March 9 and April 8, 2026. The results of the ballot will be declared on or before April 10, 2026.
Key Highlights
Appointment of Mr. Ronojit Biswas as Whole-time Director and CFO for a 3-year term starting April 1, 2026
Remote e-voting period scheduled from March 9, 2026, to April 8, 2026
Cut-off date for determining shareholder voting eligibility was February 27, 2026
Final results of the postal ballot to be announced by April 10, 2026
💼 Action for Investors
This is a routine leadership appointment; investors should monitor the voting results for confirmation of the new CFO's tenure but no immediate action is required.
GSK Pharma Appoints Ronojit Biswas as CFO and Whole-Time Director
GlaxoSmithKline Pharmaceuticals has appointed Mr. Ronojit Biswas as its new Whole-Time Director and Chief Financial Officer for a three-year term starting April 1, 2026. He succeeds Mr. Juby Chandy, who will step down on March 11, 2026, to take on a senior regional role as APAC Finance lead within the GSK Group. Mr. Biswas is a company veteran with over 25 years of experience, having previously served as CFO for GSK's operations in Brazil and Vietnam. This transition represents a planned internal succession within the global GSK framework.
Key Highlights
Mr. Ronojit Biswas appointed as CFO and Whole-Time Director for a 3-year term effective April 1, 2026.
Outgoing CFO Juby Chandy to transition to a new role leading APAC Finance within the GSK Group.
Mr. Biswas brings over 25 years of global experience with GSK, including leadership roles in Singapore, Brazil, and the UK.
The appointment was approved by the Board of Directors in a meeting held on March 2, 2026.
💼 Action for Investors
Investors should monitor the transition but can take comfort in the appointee's extensive 25-year history with the parent group. No immediate impact on stock performance is expected from this routine internal leadership rotation.
GSK Pharma Appoints Ronojit Biswas as CFO; Juby Chandy to Transition to APAC Role
GlaxoSmithKline Pharmaceuticals has announced the appointment of Mr. Ronojit Biswas as its new Whole-Time Director and Chief Financial Officer for a three-year term starting April 1, 2026. He replaces the current CFO, Mr. Juby Chandy, who will step down on March 11, 2026, to take on a senior leadership role as the head of APAC Finance within the GSK Group. Mr. Biswas is a GSK veteran with over 25 years of experience, having previously served as CFO for GSK's operations in Brazil and Vietnam. This transition reflects a planned internal succession strategy within the multinational's global framework.
Key Highlights
Mr. Ronojit Biswas appointed as CFO and Whole-Time Director for a 3-year term effective April 1, 2026.
Outgoing CFO Juby Chandy to transition to a regional role leading APAC Finance for GSK Group after March 11, 2026.
Incoming CFO Ronojit Biswas brings 25+ years of experience, including previous CFO roles in Brazil and Vietnam.
Mr. Biswas most recently served as Senior Finance Director – Global Product Strategy, based in Singapore.
The leadership change was approved during a board meeting held on March 2, 2026.
💼 Action for Investors
This is a routine leadership transition within a multinational corporation; investors should monitor if the new CFO introduces any shifts in capital allocation or cost-management strategies.
DRI Conducts Search at GlaxoSmithKline Pharmaceuticals' Mumbai Office Under Customs Act
The Directorate of Revenue Intelligence (DRI) initiated a search at the registered office of GlaxoSmithKline Pharmaceuticals in Mumbai on February 27, 2026. The action was carried out under Section 105 of the Customs Act, 1962, and concluded on February 28, 2026. The company has stated that it extended full cooperation to the authorities and that its business operations continue as usual. While the specific allegations are not yet disclosed, the company reports no immediate quantifiable impact on its financial or operational activities.
Key Highlights
Search conducted by the Directorate of Revenue Intelligence (DRI) at the Mumbai headquarters.
Action initiated under Section 105 of the Customs Act, 1962, relating to import/export regulations.
Search operation spanned two days, starting February 27 and concluding on February 28, 2026.
Company confirms business operations remain unaffected with no immediate financial impact reported.
💼 Action for Investors
Investors should remain cautious and monitor for subsequent disclosures regarding the findings of the DRI search. Any potential tax liabilities or penalties arising from this investigation could impact future earnings.
GSK Pharma Q3 FY26: Revenue Crosses ₹1,000 Cr Milestone with 35.9% EBITDA Margin
GlaxoSmithKline Pharmaceuticals reported a milestone quarter with revenue crossing ₹1,000 crores for the first time, achieving 10% consolidated growth. The company saw a significant EBITDA margin expansion of 520 basis points to 35.9%, driven by gross margin improvements and disciplined cost control. A major strategic shift is underway with the oncology foray, where the eligible patient pool for Jemperli expanded from 800 to 6,000 following regulatory approval for first-line endometrial cancer. The pediatric vaccine segment also maintained strong momentum with 11% growth during the quarter.
Key Highlights
Quarterly revenue crossed the ₹1,000 crore mark for the first time with 8.1% standalone growth.
EBITDA margins improved by 520 basis points to 35.9% despite a ₹11.8 crore one-off labor cost impact.
Oncology target patient base increased to 6,000 following RUBY-1 trial approval for first-line endometrial cancer.
Pediatric vaccine portfolio grew by 11%, led by double-digit growth in Boostrix, Varilrix, and Havrix brands.
Strong liquidity position maintained with a cash balance of ₹2,426 crores as of Q3 FY2026.
💼 Action for Investors
Investors should note the successful margin expansion and the strategic pivot toward high-value specialty oncology and adult vaccines. The significant increase in the addressable patient pool for new launches suggests a positive outlook for long-term revenue diversification.
GSK India Q3 FY26: Revenue up 8% to ₹1023 Cr, EBITDA Margins Expand to 35.9%
GlaxoSmithKline Pharmaceuticals Limited reported a steady 8.1% YoY revenue growth reaching ₹1023 crore for Q3 FY26, driven by General Medicines and a 11% growth in Pediatric Vaccines. The company achieved a significant EBITDA margin expansion of 520 bps to 35.9%, supported by gross margin improvements and an 11% rise in field productivity. PAT (before exceptional items) grew by 21.3% to ₹277 crore, reflecting strong operational leverage. The company is successfully scaling its specialty portfolio, particularly in Oncology and Adult Immunization (Shingrix), while maintaining a robust cash position of ₹2426 crore.
Key Highlights
Revenue grew 8.1% YoY to ₹1023 crore, with Pediatric Vaccines growing at 11%
EBITDA surged 26.7% YoY to ₹368 crore, with margins expanding 520 bps to 35.9%
PAT (before exceptional items) increased 21.3% YoY to ₹277 crore
Shingrix (Adult Immunization) prescriptions grew 80% YoY to 50,000 in Q3
Maintained a healthy cash balance of ₹2426 crore and improved field productivity by 11%
💼 Action for Investors
Investors should focus on the company's significant margin expansion and successful pivot towards high-growth specialty segments like Oncology and Adult Vaccines. The stock remains a strong play on operational efficiency and the premiumization of the Indian pharmaceutical market.
GSK India Q3 Revenue Crosses ₹1000 Cr, PAT at ₹277 Cr with 35.9% EBITDA Margin
GlaxoSmithKline Pharmaceuticals reported a strong Q3 FY26, with revenue from operations reaching INR 1,023 crores, representing an 8.1% growth. The company's profitability saw a significant boost as EBITDA margins expanded by 520 basis points to 35.9%, driven by improved gross margins and operating leverage. Key brands like Augmentin and Ceftum maintained market leadership, while the newly launched Oncology segment and Shingrix vaccine showed promising traction. Profit After Tax (PAT) for the quarter stood at INR 277 crores.
Key Highlights
Revenue from operations crossed the INR 1,000 crore milestone, reaching INR 1,023 crores (+8.1% YoY)
EBITDA margins expanded significantly by 520 basis points to reach 35.9%
Profit After Tax (PAT) reported at INR 277 crores for the third quarter
General Medicines portfolio saw top five brands growing ahead of the market with an Evolution Index > 100
Oncology business, launched in August 2025, is gaining traction with therapies like Jemperli and Zejula
💼 Action for Investors
Investors should note the significant margin expansion and the successful scale-up of the high-margin oncology and vaccine portfolios. The stock remains a strong defensive play in the MNC pharma space with improving growth levers.
GSK Pharma Q3 Consolidated Net Profit Rises 28.6% YoY to ₹295.6 Crore
GlaxoSmithKline Pharmaceuticals reported a strong performance for Q3 FY26, with consolidated revenue growing 9.7% YoY to ₹1,041.3 crore. Net profit surged 28.6% YoY to ₹295.6 crore, aided by operational efficiencies and an exceptional gain of ₹18 crore from land sales. Despite a ₹11.8 crore impact from new labour code regulations on employee costs, the company maintained healthy margins. Profit before tax and exceptional items grew by 24% YoY, reflecting robust underlying business momentum.
Key Highlights
Consolidated Revenue from Operations increased 9.7% YoY to ₹1,041.3 crore.
Consolidated Net Profit grew 28.6% YoY to ₹295.6 crore from ₹229.9 crore in the previous year.
Profit Before Tax (before exceptional items) rose 24% YoY to ₹382 crore.
Exceptional gain of ₹17.98 crore recorded from the sale of a non-operational land site.
Employee benefit expenses included a one-time impact of ₹11.82 crore due to new Labour Code valuations.
💼 Action for Investors
Investors should view the strong bottom-line growth and margin expansion positively, even when accounting for the exceptional gain. The stock remains a solid defensive play in the pharmaceutical sector with steady revenue growth and operational discipline.